Literature DB >> 2434734

Human atrial natriuretic peptide: plasma levels, hemodynamic, hormonal, and renal effects in patients with severe congestive heart failure.

G A Riegger, E P Kromer, K Kochsiek.   

Abstract

The effects of human alpha-natriuretic peptide (alpha-ANP) were investigated in seven patients with severe congestive heart failure by incremental bolus injections and by a continuous infusion for 30 min. alpha-ANP was measured in plasma before and after administration. We found a significant inverse correlation between basal levels of alpha-ANP and cardiac output. The administration of alpha-ANP resulted in a fall of peripheral vascular resistance, an increase in cardiac output, a relatively small decrease in blood pressure, and almost no change in pulmonary arterial pressure. alpha-ANP inhibits aldosterone and cortisol secretion and enhances diuresis and urinary sodium and potassium excretion. Plasma adrenocorticotropic hormone was reduced in two of the patients after the continuous infusion. Plasma renin concentration, norepinephrine, vasopressin, and plasma levels of 6-keto prostaglandin F1-alpha and prostaglandin E2 were unchanged. A small but significant decrease of serum potassium was observed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2434734

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure.

Authors:  G A Riegger; H Kahles; A Wagner; E P Kromer; D Elsner; K Kochsiek
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

Review 2.  Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations.

Authors:  A J Reyes; W P Leary
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 3.  Aldosterone receptor blockade in the management of heart failure.

Authors:  Emiliano A Palmieri; Bernadette Biondi; Serafino Fazio
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

4.  The vasopressor system in patients with heart failure due to idiopathic dilated cardiomyopathy--influence of the clinical stage of disease and of chronic drug treatment.

Authors:  V Mitrovic; J Thormann; P Kornecki; M Volz; H Neuss; M Schlepper
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

5.  Atrial natriuretic peptide and urinary prostaglandins in man.

Authors:  D Benzoni; J Geoffroy; B Waeber; H R Brunner; J Biollaz; J Sassard
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 6.  ANP-induced signaling cascade and its implications in renal pathophysiology.

Authors:  Franziska Theilig; Qingyu Wu
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-28

7.  Effects of intravenously administered human atrial natriuretic peptide on elevated blood pressure during surgery.

Authors:  N Iwatsuki; M Katoh; A Yasuda; S Saitoh; M Asano
Journal:  J Anesth       Date:  1989-09-01       Impact factor: 2.078

8.  Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog.

Authors:  A S Hollister; R J Rodeheffer; F J White; J R Potts; T Imada; T Inagami
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

Review 9.  Atrial Natriuretic Peptide: Structure, Function, and Physiological Effects: A Narrative Review.

Authors:  Sanjana Rao; Camilo Pena; Scott Shurmur; Kenneth Nugent
Journal:  Curr Cardiol Rev       Date:  2021

Review 10.  Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure.

Authors:  Thiago A Salles; Leonardo dos Santos; Valério G Barauna; Adriana C C Girardi
Journal:  Int J Mol Sci       Date:  2015-02-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.